Petersen Kamilla Vandsø, Selas Asier, Hymøller Kirstine Mejlstrup, Mizielinski Karol, Thorsager Maria, Stougaard Magnus, Alonso Concepcion, Palacios Francisco, Pérez-Pertejo Yolanda, Reguera Rosa M, Balaña-Fouce Rafael, Knudsen Birgitta R, Tesauro Cinzia
Department of Molecular Biology and Genetics, Aarhus University, 8000 Aarhus, Denmark.
Department of Clinical Medicine, Aarhus University, 8000 Aarhus, Denmark.
Pharmaceutics. 2021 Aug 13;13(8):1255. doi: 10.3390/pharmaceutics13081255.
: Eukaryotic topoisomerase 1 is a potential target of anti-parasitic and anti-cancer drugs. Parasites require topoisomerase 1 activity for survival and, consequently, compounds that inhibit topoisomerase 1 activity may be of interest. All effective topoisomerase 1 drugs with anti-cancer activity act by inhibiting the ligation reaction of the enzyme. Screening for topoisomerase 1 targeting drugs, therefore, should involve the possibility of dissecting which step of topoisomerase 1 activity is affected. : Here we present a novel DNA-based assay that allows for screening of the effect of small-molecule compounds targeting the binding/cleavage or the ligation steps of topoisomerase 1 catalysis. This novel assay is based on the detection of a rolling circle amplification product generated from a DNA circle resulting from topoisomerase 1 activity. : We show that the binding/cleavage and ligation reactions of topoisomerase 1 can be investigated separately in the presented assay termed REEAD (C|L) and demonstrate that the assay can be used to investigate, which of the individual steps of topoisomerase 1 catalysis are affected by small-molecule compounds. The assay is gel-free and the results can be detected by a simple colorimetric readout method using silver-on-gold precipitation rendering large equipment unnecessary. : REEAD (C|L) allows for easy and quantitative investigations of topoisomerase 1 targeting compounds and can be performed in non-specialized laboratories.
真核生物拓扑异构酶1是抗寄生虫和抗癌药物的潜在靶点。寄生虫生存需要拓扑异构酶1的活性,因此,抑制拓扑异构酶1活性的化合物可能会受到关注。所有具有抗癌活性的有效拓扑异构酶1药物均通过抑制该酶的连接反应发挥作用。因此,筛选靶向拓扑异构酶1的药物应考虑剖析拓扑异构酶1活性的哪个步骤受到影响。
在此,我们提出了一种基于DNA的新型检测方法,可用于筛选靶向拓扑异构酶1催化的结合/切割或连接步骤的小分子化合物的效果。这种新型检测方法基于对由拓扑异构酶1活性产生的DNA环所产生的滚环扩增产物的检测。
我们表明,在称为REEAD(C|L)的所示检测方法中,可以分别研究拓扑异构酶1的结合/切割和连接反应,并证明该检测方法可用于研究拓扑异构酶1催化的各个步骤中哪些受到小分子化合物的影响。该检测方法无需凝胶,结果可通过使用金上镀银沉淀的简单比色读出方法进行检测,无需大型设备。
REEAD(C|L)可轻松、定量地研究靶向拓扑异构酶1的化合物,并且可以在非专业实验室中进行。